13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-577

    Acronym: 

    CA209-577

    ACTRN/NCT /ethics: 

    NCT02743494

    Scientific title: 

    A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

    Summary of trial and patient characteristics

    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III Tumour Stream Esophageal Gastroesophageal Junction
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2016-05-23
    Molecular Target Anticipated End Date 2024-10-11
    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Esophageal Gastroesophageal Junction
    Cancer Stage All stages
    Anticipated Start Date 2016-05-23
    Anticipated End Date 2024-10-11

    Trial Summary

    The purpose of this study is to determine whether Nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

    Lay Summary

    A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

    Sponsor / Cooperative group

    Bristol-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Nimit Singhal Recruiting
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 70742342 Recruiting